Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMDNASDAQ:SBBPNASDAQ:SBTXNASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$12.50-16.4%$12.21$3.61▼$17.43$847.81M1.621.32 million shs9.88 million shsSBBPStrongbridge Biopharma$2.00$2.09$1.85▼$4.26$135.66M1.58866,464 shs684,684 shsSBTXSilverback Therapeutics$18.20+0.7%$14.55$2.80▼$8.97$656.26M0.6337,931 shs3.88 million shsSVRASavara$2.21$2.68$1.89▼$5.11$381.97M0.321.27 million shs2.32 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix0.00%-8.16%+2.29%+85.46%+201.20%SBBPStrongbridge Biopharma0.00%0.00%0.00%0.00%0.00%SBTXSilverback Therapeutics+0.66%+15.19%+22.56%+45.72%+137.91%SVRASavara0.00%+7.28%-1.34%-24.05%-42.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRMDCorMedix1.5948 of 5 stars3.61.00.00.02.00.00.6SBBPStrongbridge BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASVRASavara2.3819 of 5 stars3.31.00.00.02.23.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 3.17Buy$16.6733.33% UpsideSBBPStrongbridge Biopharma 0.00N/AN/AN/ASBTXSilverback Therapeutics 0.00N/AN/AN/ASVRASavara 2.60Moderate Buy$5.60153.39% UpsideCurrent Analyst Ratings BreakdownLatest SBBP, SVRA, CRMD, and SBTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.006/23/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.006/20/2025CRMDCorMedixRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$13.00 ➝ $17.005/29/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$6.00 ➝ $2.005/28/2025SVRASavaraEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetIn-Line ➝ In-Line$3.00 ➝ $2.005/28/2025SVRASavaraGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $8.005/28/2025SVRASavaraWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.005/7/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $15.005/6/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.004/9/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/8/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$43.47M19.50N/AN/A$1.40 per share8.93SBBPStrongbridge Biopharma$30.73M4.41N/AN/A$0.98 per share2.04SBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/ASVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$17.93M$0.2256.8213.30N/A20.81%22.57%17.02%8/13/2025 (Estimated)SBBPStrongbridge Biopharma-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/ASBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ASVRASavara-$95.88M-$0.48N/AN/AN/AN/A-65.88%-52.35%8/11/2025 (Estimated)Latest SBBP, SVRA, CRMD, and SBTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SVRASavara-$0.12-$0.12N/A-$0.12N/AN/A5/6/2025Q1 2025CRMDCorMedix$0.25$0.30+$0.05$0.30$38.90 million$39.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A4.213.99SBBPStrongbridge Biopharma0.383.002.95SBTXSilverback TherapeuticsN/A67.8767.87SVRASavara0.2014.9114.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%SBBPStrongbridge Biopharma52.03%SBTXSilverback Therapeutics74.89%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix5.30%SBBPStrongbridge Biopharma5.10%SBTXSilverback Therapeutics34.40%SVRASavara5.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3067.82 million64.23 millionOptionableSBBPStrongbridge Biopharma7267.83 millionN/AOptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableSVRASavaraN/A172.84 million163.63 millionOptionableSBBP, SVRA, CRMD, and SBTX HeadlinesRecent News About These CompaniesSavara Inc. (NASDAQ:SVRA) Receives $7.17 Average Price Target from AnalystsJune 28 at 2:11 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 27 at 10:00 AM | prnewswire.comSavara Independent Director Acquires 177% More StockJune 25, 2025 | finance.yahoo.comSavara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from AnalystsJune 25, 2025 | marketbeat.comRichard J. Hawkins Purchases 48,225 Shares of Savara Inc. (NASDAQ:SVRA) StockJune 24, 2025 | insidertrades.comInsider Buying: Savara Inc. (NASDAQ:SVRA) Director Buys 48,225 Shares of StockJune 23, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 22, 2025 | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 22, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 18, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 16, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 13, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 12, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 11, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 9, 2025 | accessnewswire.comAsavara elects board members and approves proposals at annual meetingJune 8, 2025 | investing.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 7, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 6, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 5, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 4, 2025 | accessnewswire.comAMillennium Management LLC Grows Stake in Savara Inc (NASDAQ:SVRA)June 4, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRAJune 3, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBBP, SVRA, CRMD, and SBTX Company DescriptionsCorMedix NASDAQ:CRMD$12.50 -2.46 (-16.44%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$12.48 -0.02 (-0.12%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Strongbridge Biopharma NASDAQ:SBBPStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.Silverback Therapeutics NASDAQ:SBTX$18.20 +0.12 (+0.66%) As of 06/27/2025Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Savara NASDAQ:SVRA$2.21 0.00 (0.00%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$2.18 -0.02 (-1.13%) As of 06/27/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
